Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

This study is testing whether psilocybin (the active compound in 'magic mushrooms,' given in a controlled medical setting) can safely reduce depression in people with mild cognitive impairment or early Alzheimer's disease. It is one of the first trials to explore this in people with dementia-related conditions. **You may be eligible if...** - You have been diagnosed with mild cognitive impairment or early/mild Alzheimer's disease - You have a cognitive test score (MMSE) above 18 and MoCA score below 26 - You show at least mild depressive symptoms on a standard scale - If you take antidepressants (SSRIs, SNRIs, or bupropion up to 300 mg/day), the dose has been stable for at least 2 months - You have a close friend or family member who can act as a study observer **You may NOT be eligible if...** - You are 86 years old or older - You are currently taking antipsychotics, MAO inhibitors, or antidepressants other than SSRIs, SNRIs, or bupropion - You have a history of serious psychiatric conditions (such as schizophrenia or bipolar disorder with psychosis) Talk to your doctor to see if this trial is right for you.